Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Net Margin (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Net Margin data on record, last reported at 3015.4% in Q4 2025.

  • For Q4 2025, Net Margin fell 301835.0% year-over-year to 3015.4%; the TTM value through Dec 2025 reached 565.38%, down 59650.0%, while the annual FY2025 figure was 565.38%, 59650.0% down from the prior year.
  • Net Margin reached 3015.4% in Q4 2025 per TRDA's latest filing, down from 2731.1% in the prior quarter.
  • Across five years, Net Margin topped out at 80.97% in Q3 2023 and bottomed at 3015.4% in Q4 2025.
  • Average Net Margin over 3 years is 677.0%, with a median of 49.03% recorded in 2024.
  • Peak YoY movement for Net Margin: surged 20051bps in 2024, then crashed -301835bps in 2025.
  • A 3-year view of Net Margin shows it stood at 22.81% in 2023, then surged by 113bps to 2.95% in 2024, then tumbled by -102154bps to 3015.4% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 3015.4% in Q4 2025, 2731.1% in Q3 2025, and 2211.54% in Q2 2025.